Paper Details

  1. Home
  2. Paper Details

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.

Author: , Bianchi PorroGabriele, BollaniSimona, FelsenbergDieter, GraffnerHans, Haptén-WhiteLouise, IsraeliEran, LjunghallSverker, MillsPeter R, PerssonTore, SchoonErik J, StockbrüggerReinhold W, VatnMorten

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Budesonide treatment preserves bone mass better than prednisolone in corticosteroid-naive patients with active ileocecal Crohn's disease. Both treatments are equally effective in both corticosteroid-free and corticosteroid-dependent groups, but budesonide causes fewer corticosteroid side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: Osteoporosis frequently occurs in Crohn's disease, often because of corticosteroids. Budesonide as controlled release capsules is a locally acting corticosteroid with low systemic bioavailability. We investigated its effects on bone compared with prednisolone. METHODS: In 34 inte...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s1542-3565(04)00662-7

データ提供：米国国立医学図書館（NLM）

Budesonide vs Prednisolone: A Tale of Two Corticosteroids

The world of inflammatory bowel disease (IBD) is a challenging one, with patients seeking relief from chronic inflammation and its associated complications. This study focuses on the effects of two corticosteroids, budesonide and prednisolone, on bone mineral density in patients with Crohn's disease. The researchers conducted a double-blinded, randomized trial comparing the effects of these two medications on bone health, disease activity, side effects, and quality of life in patients with IBD. The study found that budesonide, a locally acting corticosteroid, was associated with better preservation of bone mass compared to prednisolone in patients who had never received corticosteroids. Furthermore, budesonide caused fewer corticosteroid-related side effects while maintaining similar efficacy to prednisolone.

Budesonide: A Gentle Touch for Bone Health

The study reveals that budesonide, a locally acting corticosteroid, can help preserve bone mass in patients with Crohn's disease, especially those who have never received corticosteroids. This finding is significant because it suggests that budesonide could be a better option for patients at risk of osteoporosis, a common complication of IBD.

Navigating the Desert of IBD: Seeking Relief and Preserving Health

This research provides valuable insights into the management of Crohn's disease. The study suggests that budesonide, like a cool spring in the desert, can offer relief from inflammation while minimizing the risk of bone loss. However, it's important to note that this research is specific to patients with Crohn's disease and further studies are needed to confirm the effectiveness of budesonide in other IBD populations.

Dr.Camel's Conclusion

This study provides evidence that budesonide can be an effective treatment option for Crohn's disease, especially in patients who have never received corticosteroids. The research suggests that budesonide can help preserve bone mass and reduce the risk of corticosteroid-related side effects. Like a wise camel navigating a treacherous desert, researchers continue to seek new strategies to manage IBD, improving the lives of patients and offering a pathway towards a healthier future.

Date :
  1. Date Completed 2005-06-03
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

15704045

DOI: Digital Object Identifier

10.1016/s1542-3565(04)00662-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.